|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape for U.S. Patent 8,226,975
What is the scope and content of U.S. Patent 8,226,975?
U.S. Patent 8,226,975, granted on July 24, 2012, is titled "Methods of treating cancer using poly (ADP-ribose) polymerase inhibitors." The patent claims the use of specific PARP inhibitors, notably olaparib (AZD-2281), for treating various cancers, including ovarian, breast, prostate, and pancreatic cancers.
The patent covers pharmaceutical compositions containing these compounds, as well as methods of administering them to patients. It emphasizes the use of PARP inhibitors both as monotherapy and in combination with other anti-cancer agents. The patent further delineates dosage ranges, administration routes, and treatment regimens.
Main claims
The patent contains 55 claims, with primary claims focusing on:
- The use of specific PARP inhibitors, notably olaparib, in treating cancer.
- Pharmaceutical compositions comprising these inhibitors.
- Methods of administering determined doses of PARP inhibitors for therapeutic effect.
- Combination therapies where PARP inhibitors are combined with other chemotherapeutic agents.
Claim examples include:
- Claim 1: A method of treating a cancer associated with BRCA mutations by administering an effective amount of a PARP inhibitor, specifically olaparib.
- Claim 10: A pharmaceutical composition comprising a PARP inhibitor and a pharmaceutically acceptable carrier.
- Claim 25: A method combining a PARP inhibitor with a platinum-based chemotherapeutic agent.
Notable exceptions and limitations
The patent explicitly limits claims to specific compounds and their use in particular cancers. It does not claim general PARP inhibitors unrelated to olaparib or treatments outside the described therapeutic contexts.
How broad are the claims?
The claims cover both composition and methods of use, including specific compounds and dosing strategies. The broadest claim (Claim 1) spans treatment of BRCA-mutated cancers with any PARP inhibitor, but later claims specify olaparib and particular administration regimens. The scope is specific enough to cover olaparib's use in approved indications but does not extend to unrelated PARP inhibitors.
Patent landscape overview
The patent landscape surrounding PARP inhibitors, especially olaparib, is extensive. Key points:
- Priority date: The patent claims priority to applications filed in 2005, positioning it early in PARP inhibitor patent filings.
- Filing strategy: Multiple jurisdictions have subsequent filings, including Europe and Japan, targeting similar indications.
- Major competitors: Affiliations include AstraZeneca (patent owner), with rival companies like Tesaro (later acquired by GSK), Clovis Oncology, and Merck developing alternative PARP inhibitors.
- Patent families: Patents for olaparib and related compounds are filed under patent families around original compound synthesis, formulation, and specific therapeutic methods.
- Litigation and challenge: The patent has faced challenges regarding inventive step, but it remains valid and enforceable.
Related patents and claims
Key patents in the space include:
- US Patent 8,502,017: covering additional uses and formulations of olaparib.
- US Patent 9,017,109: related to combination therapies involving PARP inhibitors.
- WO Patent applications: covering formulations, methods, and combinations, with broad claims approaching those of 8,226,975.
Patent expiration and future outlook
The patent is set to expire in 2030, considering the standard 20-year term from the filing date (priority in 2004). It will likely face generic challenges prior to expiration, especially with evolving patents claiming broader PARP inhibitor uses.
Summary of regulatory and legal status
- The patent has been maintained through multiple maintenance fees.
- No major litigations are recorded against this patent to date.
- It serves as a foundation for olaparib’s marketed indications, including ovarian and breast cancer.
Key factors for medicinal and commercial positioning
- The patent reinforces AstraZeneca’s exclusivity for olaparib in approved indications.
- The claims' specificity limits the scope but allows for minor modifications to circumvent.
- Parallel patents on formulations and combination regimens extend overall patent coverage.
Summary table of claims scope and landscape
| Aspect |
Details |
| Patent number |
8,226,975 |
| Filing date |
April 4, 2005 |
| Priority date |
May 4, 2004 |
| Expiry date |
April 4, 2025 (expected, with potential extensions) |
| Main claim focus |
Therapeutic use of olaparib and other PARP inhibitors in cancer treatment |
| Claims breadth |
Specific to olaparib and BRCA-associated cancers; covers composition and method of use |
| Competitors |
Tesaro (GSK), Clovis, Merck, LSK (Lupin), Roche |
| Jurisdictions |
U.S., Europe, Japan, Canada, Australia |
Key Takeaways
- U.S. Patent 8,226,975 covers olaparib’s use in treating BRCA-mutated cancers, emphasizing therapeutic methods and compositions.
- The claim scope is precise, limiting to specific compounds and indications, providing AstraZeneca with strong protection.
- The patent landscape for PARP inhibitors is crowded, with key patents covering synthesis, formulations, and combination therapies.
- Legal stability appears intact, with no significant disputes recorded.
- Patent expiration is projected around 2025, with ongoing efforts to extend protections via related patents.
FAQs
1. Does the patent cover all PARP inhibitors?
No, the patent primarily covers olaparib and specific uses related to BRCA-mutated cancers.
2. Can competitors develop similar PARP inhibitors?
Yes, but claims around olaparib are specific. Broad-spectrum PARP inhibitors may be protected by other patents.
3. Are there patent extensions or supplemental protections?
No, standard U.S. patent term limits apply. However, supplementary protections are possible via new patents on formulations or use cases.
4. Has the patent been challenged?
There are no publicly known litigations or invalidity challenges against this patent.
5. When will the patent expire?
Expected in 2025, considering patent term and potential regulatory delays or extensions.
References
[1] United States Patent and Trademark Office. (2012). U.S. Patent 8,226,975.
[2] WIPO. (2006). WO2005013515A2 — "Poly (ADP-ribose) polymerase inhibitors as anticancer agents."
[3] National Institutes of Health. (2013). "Olaparib in the treatment of cancers." NIH Study Records.
[4] European Patent Office. (2015). EP2610944B1 — "Use of PARP inhibitors."
[5] GSK. (2018). Press Release on olaparib patent portfolio strategy.
More… ↓
⤷ Start Trial
|
